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t 3  ABSTRACT 
 
The link between higher procedure volume and better outcomes for surgical procedures is well established. 
We aimed to determine if procedure volume affected inpatient mortality in patients undergoing transjugular 
intra-hepatic portosystemic shunt (TIPS). An epidemiological analysis of an all-payer database recording 
hospitalizations during 2013 in the United States (Nationwide Readmissions Database) was performed. All 
patients’ ≥18 years old undergoing TIPS during a hospital admission (n=5529) without concurrent or prior liver 
transplantation were selected. All-cause inpatient mortality was assessed. Risk-adjusted mortality was 
assessed for hospitals categorized into quintiles based on annual TIPS volume; very low (1-4/year), low (5-
9/year), medium (10-19/year), high (20-29/year), and very high (≥30/year). TIPS were placed in 5529 patients 
(57±10.9 years; 37.5% female). Mortality decreased with rising annual TIPS volume (13% for very low to 6% 
for very high volume hospitals; p<0.01). Elective admissions were more common in hospitals with higher 
annual TIPS volume (20.3% for very low to 30.8% for very high; p<0.01). On multivariate analysis, compared 
to hospitals performing ≥30 TIPS per year, only hospitals performing 1-4/year (aOR: 1.9, 95%CI:1.21-3.01; 
p=0.01), 5-9/year (aOR: 2.0, 95%CI:1.25-3.17; p<0.01), and 10-19/year (aOR: 1.9, 95%CI:1.17-3.00; p=0.01) 
had higher inpatient mortality (20-29/year [aOR: 1.4, 95%CI:0.84-2.84; p=0.19]). The absolute difference 
between risk-adjusted mortality rate for very low volume and very high volume hospitals was 6.1% (13.9% vs. 
7.8%). TIPS volume of ≤20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk 
factors for inpatient mortality in patients with both elective and emergent admissions. Conclusions: The risk of 
inpatient mortality is lower in hospitals performing ≥20 TIPS per year. Future research exploring preventable 
factors for higher mortality and benefits of patient transfer to higher volume centers is warranted. 
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t 4  The association between hospitals with higher annual procedure volume and improved survival has been 
demonstrated for most major surgical procedures.(1–4) Better patient outcomes at higher volume centers have 
also been reported for percutaneous cardiovascular interventions, such as coronary and valvular procedures, 
peripheral arterial interventions, and endovascular abdominal aortic aneurysm repair (EVAR).(5–10) Building 
on these findings, several studies have shown that increasing referral of elective EVAR cases to high-volume 
centers by a process known as regionalization leads to improved patient outcomes.(11–14) However, such 
study has not yet been expanded to percutaneous procedures in non-cardiovascular patients, where 
interventional procedures can be complex, associated with an operator learning curve, and are performed in 
critically-ill patients. 
 
Transjugular intrahepatic portosystemic shunt (TIPS) placement for treating sequalae of portal hypertension 
requires a high degree of technical and clinical experience to achieve optimal patient outcomes.(15,16) A 
recent study of the Nationwide Inpatient Sample (NIS) reported a reduction in inpatient mortality during 
admissions with TIPS placement from 12.5% in 2003 to 10.6% in 2012.(17) Studies have demonstrated that 
variation in inpatient mortality for patients with cirrhosis can be a result of hospital-level factors.(18) The annual 
hospital volume of admissions for patients with cirrhosis or esophageal variceal bleeding alone does not 
account for variations observed in inpatient mortality, although patients at high volume hospitals with these 
conditions were more likely to undergo TIPS placement, suggesting that additional study on the influence of 
TIPS volume on inpatient outcomes is likely warranted.(18,19)  
 
Given the known variations in mortality for patients with cirrhosis and relationship between annual procedure 
volume and inpatient mortality for image-guided procedures, we sought to identify pre-procedure patient, 
hospital and volume characteristics that may explain variations in mortality after TIPS procedures. 
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Data Source: The National Readmission Database (NRD) is a database developed by the Healthcare Cost and 
Utilization Project (HCUP) that includes all hospitalizations during 2013 in 21 geographically diverse states.(20) 
This all payer (insured and uninsured) database contains data from approximately 14 million discharges, 
representing 49.1% of all US hospitalizations. It records de-identified patient and hospital demographics, 
discharge diagnoses, inpatient procedures, length of stay, and discharge status. In addition, it includes 29 
Elixhauser co-morbidity measures that are assigned using the Agency for Healthcare Research and Quality 
(AHRQ) comorbidity software.(21) These measures identify co-existing medical conditions not directly related 
to the principal diagnosis and likely to have originated prior to the hospital stay. It also includes All Patient 
Refined Diagnosis Related Groups (APR-DRGs) severity measures assigned using software developed by 3M 
Health Information Systems to adjust for case-mix severity. The APR-DRG risk of mortality score has been 
validated as the most discriminative and predictive mortality risk score for cirrhotic patients in the NIS, a 
smaller HCUP database (20% sample, 7.8 million annual discharges).(22) In contrast to the NIS, the NRD links 
all hospitalizations for each patient allowing analysis at a patient rather than discharge level and providing the 
ability to control for multiple hospitalizations with a TIPS procedure code for the same patient. To ensure 
generalizability, discharge weights were developed in the NRD to produce national estimates after the data 
were stratified, by patient and hospital characteristics. National estimates were calculated by applying 
discharge weights prior to analysis.  
 
The study was reviewed by the institutional review board as appropriate for exemption from institutional review 
board oversight because no protected health information was available in the data. 
 
Study population: Procedure diagnosis codes for all hospitalizations in the database were searched for TIPS 
procedures. Inclusion criteria were International Classification of Diseases 9th version (ICD-9) procedure code 
39.1 (Intra-abdominal venous shunt), and age ≥18 years. Since placement of multiple TIPS in a single patient 
is rare, patients with multiple ICD-9 codes of 39.1 (n=58) were excluded. Liver transplantation changes 
outcomes for cirrhotic patients, therefore patients with ICD-9 procedure code 50.5* (liver transplantation) 
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Patients were categorized by age, gender, insurance status, and etiology of liver disease (alcoholic liver 
disease, viral liver disease, non-alcoholic fatty liver disease [NAFLD], other). Severity of liver disease is an 
important predictor of mortality after TIPS, but the absence of laboratory data precluded assessment of 
validated instruments such as Child-Pugh or Model for End-Stage Liver Disease (MELD) scores. Therefore, 
features of hepatic decompensation were controlled by using the presence or absence of ICD-9-CM diagnosis 
and procedure codes for ascites or hydrothorax, hepatic encephalopathy, hepatorenal syndrome, spontaneous 
bacterial peritonitis, and variceal bleeding (Appendix Table 1). Co-morbidities were assessed by the presence 
of 28 AHRQ co-morbidity measures (comorbidity measure for liver disease was excluded from analysis) and 
APR-DRG risk of mortality (likelihood of dying: minor, moderate, major, extreme).  
 
Index hospitalizations were categorized by mode of admission (elective vs. emergent), length of stay and 
presence or absence of intensive care unit (ICU) admission. ICU admission was assessed using ICD-9 
diagnosis codes of circulatory shock and a previously described classification of ICD-9 procedure codes 
typically found in cirrhotic ICU patients (Appendix Table 1).(23) Hospitalizations were further characterized by 
the presence of medical diagnoses that can cause (or result from) prolonged or complicated hospitalizations 
(acute renal failure, infection, diabetes, coagulopathy, respiratory failure, electrolyte imbalance [hyponatremia, 
hypokalemia, acidosis], and substance abuse) (Appendix Table 1). 
 
Hospitals co-variates included ownership (government, non-federal; private, non-profit; private, investor-
owned), bed size (small, medium, large), teaching status (metropolitan teaching, metropolitan non-teaching, 
non-metropolitan), and location by metropolitan size (metropolitan area with >1 million residents, metropolitan 
area with <1 million residents and micropolitan areas). Patients with ICD-9 procedure code 50.* (liver 
transplantation) during hospitalizations in the entire database were used to identify transplant hospitals. 
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visual estimation); very low (1-4/year; n=589), low (5-9/year; n=606), medium (10-19/year; n=502), high (20-
29/year; n=394) and very high (≥30/year; n=497). The primary outcome of interest was inpatient mortality. 
 
Statistical analysis: Descriptive statistics were obtained using Pearson’s chi-square for dichotomous or 
categorical variables and ANOVA for continuous variables. Multivariate analysis was performed using 
generalized linear mixed model for logistic regression in order to correct the within-hospital correlations. Based 
on clinical and statistical significance, factors associated with higher inpatient mortality were selected for 
multivariate analysis. Age was included despite non-significant p-values based upon conceptual hypotheses 
that it may have an impact on mortality when controlling for other predictors. Variceal bleeding, alcoholic vs. 
non-alcoholic etiology of liver disease, infection, and diabetes were included given significant p-values as well 
as prior studies showing an effect on mortality with inclusion of these variables. Hospital-level predictors were 
non-significant across bivariate and multivariate analyses and thus were excluded from the final multivariable 
regression. Pearson correlation test was used for testing multicollinearity between any of the two co-variates in 
the multivariate model, and co-variates with an r above 0.6 were considered to have high interactions. 
Transplant hospital status was highly correlated with hospital TIPS procedure volume (Pearson correlation 
r=0.788), so only procedure volume was included in the final model. Adjusted mortality rates were calculated 
using average patient characteristics by back-transforming predicted mortality from the final model. 
 
Due to significant differences in observed mortality rate between patients with elective and emergent 
admissions, two separate generalized linear mixed models were fit to these sub-cohorts. Considering the 
sample size of the two sub-cohorts, volume of TIPS was regrouped into two groups (1-19 TIPS/year and ≥20 
TIPS/year), and patient income quartile by zip code was excluded from the models. Discrimination and 
goodness-of-fit statistics were calculated for each model. For our full model, there were 16 total variables 
(including dummy variables) with a c-statistic of 0.776; the models for elective admissions and emergent 
admissions have 9 variables, and c-statistics of 0.895 and 0.732, respectively. Our c-statistic was within the 
range reported for models investigating volume-outcome relationships for surgical procedures.(24,25) All 
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Institute Inc.), and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, 
NY: IBM Corp.) software. 
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Overall, 5529 adult atients underwent TIPS without prior or concurrent liver transplantation during the index 
admission. Inpatient mortality for this cohort was 10.5% (583/5529). There were 278/443 (63%) hospitals with 
1-4 TIPS/year, 95/443 (21%) hospitals with 5-9 TIPS/year, 39/443 (9%) hospitals with 10-19 TIPS/year, 18/443 
(4%) hospitals with 20-29 TIPS/year, and 13/443 (3%) hospitals with ≥30 TIPS/year. Inpatient mortality, 
characteristics of patients, hospitalizations, and hospitals for each quintile are reported in Table 1. Hospitals 
with ≥20 TIPS/year (7% of hospitals) and the lowest inpatient mortality were exclusively metropolitan teaching 
hospitals. 
 
In univariate analysis, lower TIPS volume, increased patient age, non-elective admission, primary payer of 
Medicaid or self-pay, alcoholic etiology of liver disease (vs non-alcoholic, viral, other), median household 
income quartiles for patient’s ZIP code, variceal bleeding, diabetes, and infection were associated with 
inpatient mortality (Appendix table 2).  
 
Multivariate analysis revealed that increasing age, variceal bleeding, and/or infection during the admission, 
chronic conditions of coagulopathy and renal failure, higher income quartiles for patient ZIP code, and three 
lower annual hospital procedure volume groups were independently associated with higher odds of mortality 
(Table 2). Compared to hospitals performing ≥30 TIPS per year, only hospitals performing 1-4/year (aOR: 1.9, 
95%CI:1.21-3.01; p=0.01), 5-9/year (aOR: 2.0, 95%CI:1.25-3.17; p<0.01) and 10-19/year (aOR: 1.9, 
95%CI:1.17-3.00; p=0.01) had higher odds of inpatient mortality (20-29/year [aOR: 1.4, 95%CI:0.84-2.84; 
p=0.19]). Similarly, the adjusted mortality rate of the lowest quintile hospitals was nearly twice the adjusted 
mortality rate for the highest quintile (13.9% vs. 7.8%; Figure 1).  
 
Mode of admission: Differentiating patients with an elective vs. emergent mode of admission, the unadjusted 
inpatient mortality rate decreased with increasing annual TIPS volume for both types of admissions. For 
elective admissions, the unadjusted mortality rate for the lowest quintile of annual TIPS volume (1-4 TIPS/year; 
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t 107.9%) was 2.7 times the mortality rate for the highest quintile of TIPS volume (≥30 TIPS/year; 3.1) (Figure 2). For emergent admissions, the unadjusted mortality rate for the lowest quintile (14.2%) was 1.9 times the 
mortality rate for the highest quintile (7.5%) (Figure 3). No significant interaction was noted between annual 
TIPS volume and mode of admission (Tier 1*mode, p=0.379; Tier 2*mode, p=0.774; Tier 3*mode, p=0.498; 
tier 4*mode, p=0.181). 
 
A multivariate model to analyze patients with elective admissions found that variceal bleeding and infection 
during the index admission and coagulopathy were independently associated with higher odds of inpatient 
mortality (Appendix Table 3). Adjusted odds for mortality in hospitals with 1-19 TIPS per year was significantly 
higher than those for ≥20 TIPS per year (aOR 2.5, p=0.04). Similarly multivariate analysis of patients with 
emergent admissions found increase in age, variceal bleeding and infection during the index admission, and 
coagulopathy and renal failure as co-morbidities were independently associated with higher odds of inpatient 
mortality (Appendix Table 4). Adjusted odds for mortality in hospitals with 1-19 TIPS per year was also 
significantly higher than those for ≥20 TIPS per year (aOR 1.5, p=0.01). 
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In this national study of TIPS procedures, higher-volume hospitals had fewer deaths during the index 
admission. The absolute difference in adjusted mortality rates between very low and very high volume 
hospitals was large (6.1%), compared to similar results for open surgical procedures (0.2%-12.5%).(1) 
Specifically, 20 TIPS/year represented an annual threshold beyond which inpatient mortality was better for 
both emergent and elective procedures. Hospitals with ≥20 TIPS/year were exclusively metropolitan teaching 
hospitals but accounted for only 38% of all TIPS procedures. Finally, in addition to annual TIPS volume, 
inpatient mortality was higher for patients with variceal bleeding, nosocomial infections, and coagulopathy, 
independent of other factors. 
 
Two main hypotheses seek to explain the volume-outcome relationship for procedures.(26) The practice-
makes-perfect hypothesis posits that physicians and hospital personnel, who see more patients, develop better 
skills resulting in better outcomes. The selective-referral hypothesis states that hospitals and/or physicians with 
better outcomes attract more patients. In addition, studies in the surgical literature have identified several 
procedure-specific causes for the volume-outcome relationship. These include annual operator volume (e.g. in 
percutaneous cardiovascular procedures), complication rates and failure to rescue from complications.(24)  
 
The selective-referral hypothesis appears to explain some of the findings in this study. Hospitals performing 
≥20 TIPS/year were exclusively metropolitan teaching hospitals and more than 80% of hospitals in the top two 
quintiles performed liver transplantation. Therefore, it is plausible that patients benefitting from better outcomes 
at high-volume hospitals had end-stage liver disease requiring referral to these liver transplantation centers for 
management. Patients undergoing liver transplantation during the index admission were excluded from 
analysis, therefore the lower inpatient mortality was likely related to a combination of better patient selection, 
more experienced operators, and improved peri- and post-procedural care rather than liver transplantation 
performed to rescue patients with poor outcomes after TIPS. This is also supported by the lack of statistical 
significance of APR-DRG risk of mortality, the most discriminative and predictive mortality risk score in cirrhotic 
patients, for inclusion in our multivariate model. Of the significant risk factors revealed by the multivariate 
Page 11 of 28
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t 12model, variceal bleeding and coagulopathy are inherent to this population due to portal hypertension and liver dysfunction. However, the presence of nosocomial infections (e.g. pneumonia, clostridium difficile, urinary 
tract infection) as an independent risk factor for mortality may represent a modifiable risk factor for improving 
outcomes in these atients, distinct from annual TIPS volume.   
 
The practice-makes-perfect hypothesis can also potentially apply to the TIPS procedure. Traditional 
fluoroscopic techniques for TIPS creation rely on blind trans-hepatic portal vein punctures guided by anatomic 
knowledge and operator experience. A small study revealed significant differences in procedure times between 
experience and inexperienced physicians.(27) Similarly, a study evaluating the use of intra-vascular ultrasound 
for TIPS creation found that direct visualization of the TIPS needle during trans-hepatic punctures reduced 
procedural time and intra-procedural complications, however this effect was limited to inexperienced operators 
(<20 TIPS placed).(28) These findings may support the practice-makes-perfect hypothesis as it relates to 
technical success. However, specific details for TIPS procedures, such as operator identity and procedure 
time, were not available in the NRD therefore whether more operator experience results in better outcomes 
after TIPS is unknown. 
 
Based on our results, it appears the selective-referral hypothesis best explains our results. It appears that 
inpatient mortality was primarily driven by the decision making of multidisciplinary teams (likely including 
hepatologists, surgeons, interventional radiologists, and intensivists) regarding patient selection, peri-
procedural care, and recognizing or rescuing from complications of care. These factors, as well as factors such 
as endoscopist skill and effective balloon tamponade, likely contribute to improved outcomes. Future work 
either investigating the interplay between these factors or standardizing and disseminating best care practices 
will likely lead to improvement in the care for these patients. 
 
The volume-outcome relationship that was observed in this study with a 20 TIPS/year threshold and risk 
factors for inpatient mortality persisted in a sub-analysis looking at elective and emergent admissions. 
Emergent admissions (which typically occur for variceal bleeding) were more common than elective 
admissions (which typically occur for ascites) across hospital quintiles but hospitals in lower volume quintiles 
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t 13had a higher percentage of emergent admissions. Regionalization of elective TIPS procedures to higher volume centers has the potential to improve patient outcomes, similar to how this process has improved 
outcomes for elective EVAR.(13,14)  
 
However, the benefit of transfers to higher volume TIPS centers for patients requiring emergent admissions is 
less clear. First, most patients with emergent admissions likely represent patients with variceal bleeding, for 
whom medical and endoscopic management represent first-line treatment.(29) Second, a volume-outcome 
analysis of all patients with esophageal variceal bleeding in the NIS between 1998-2005 did not show a 
survival benefit for treatment at a high-volume hospital.(19) Third, inpatient mortality (75%) and 6-week 
mortality (35%) for uncovered TIPS in the salvage setting is high and despite the lack of robust data for 
covered TIPS, it may be unsafe to transfer the majority of these acutely sick patients.(30) However, recent 
guidelines have recommended the use of early covered TIPS placement (<72 hours after index variceal 
bleeding) in selected patients after successful endoscopic therapy.(31,32) Given the high adjusted odds ratio 
of variceal bleeding as an indication for TIPS placement in patients with both elective and emergent 
admissions (Appendix Table 3 and 4), these patients represent a sub-set of patients currently undergoing TIPS 
at low-volume hospitals who may derive benefit from a regionalization strategy, regardless of mode of 
admission as long as safe transfer can be arranged.  
 
Several limitations are inherent to our study design. First, the use of an administrative database subjects our 
findings to coding error and reduced specificity compared to clinical assessments with discriminative properties 
in TIPS patients e.g. MELD score. Although the c-statistic for the predictive models developed in this analysis 
demonstrate good discriminative ability, it is still possible that unmeasured confounders (e.g. clinical or 
laboratory assessments) may affect the model. Second, although definitions for conditions such as variceal 
bleeding, infection, and ICU stays were derived from prior studies in similar cohorts, no validation studies 
comparing the accuracy of these definitions with medical record level data exist. Third, specific patient level 
data is not available nor accurately obtainable using ICD-9 codes e.g. covered vs. uncovered stent use, 
indication of TIPS (e.g. ascites, variceal bleeding, Budd-Chiari sydrome), total procedure time, post-TIPS 
clinical course. Finally, outcomes in this study were limited to in-patient mortality rather than post-discharge 
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t 14mortality. However, similar studies on other procedures have previously shown good correlation between inpatient and 30-day mortality and no difference in the volume-outcome relationship when either of these 
outcomes is used.(1,33)  
 
In conclusion, hospitals performing more than 20 TIPS per year have lower inpatient mortality compared to 
hospitals with lower annual TIPS volume. Standardizing patient selection, peri-procedural care, and a 
regionalization strategy for patients requiring elective TIPS may lead to improvement of outcomes at low-
volume hospitals. 
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t 15 FIGURE LEGENDS: 
 
Figure 1: Adjusted inpatient mortality for rate patients undergoing TIPS in 2013 according to quintile of annual 
hospital TIPS volume. Mortality rate was adjusted for: age, presence of alcoholic liver disease, emergent 
admission, variceal bleeding, infection, diabetes, quintiles of annual procedure volume, AHRQ comorbidity 
measures for congestive heart failure, coagulopathy and renal failure, and income quartile per patient zip code.  
 
Figure 2: Observed mortality rate and indication for TIPS placement by quintiles of annual hospital TIPS 
volume for elective admissions. 
 
Figure 3: Observed mortality rate and indication for TIPS placement by quintiles of annual hospital TIPS 
volume for non-elective admissions. 
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t Full cohort 1-4 5-9 10-19 20-29 ≥30 p value N of admissions n=5529 n=1202 (22%) n=1102 (20%) n=1076 (19%) n=982 (18%) n=1167 (21%) n % n % n % n % n % n %  Inpatient mortality 583 10.5 155 12.9 146 13.2 125 11.6 88 8.9 70 6.0 <0.01 
Patient Demographics 
Age (year) 57±10.9 58±11.3 57±11.7 57±11.1 56±10.7 57±9.9 0.02 
Female   2071 37.5 443 36.9 397 36.0 360 33.5 423 43.1 448 38.4 <0.01 
Etiology of liver disease <0.01 
Alcoholic 2498 45.2 622 51.7 533 48.4 523 48.6 362 36.9 458 39.3 
 
NAFLD 1343 24.3 278 23.1 260 23.6 260 24.1 244 24.8 301 25.8 
Viral 1049 19.0 199 16.5 207 18.8 204 18.9 161 16.4 278 23.8 
Other 640 11.6 104 8.6 102 9.3 90 8.4 215 21.9 129 11.1 
Insurance status <0.01 
Medicare 2132 38.7 437 36.6 428 38.9 426 39.7 344 35.0 497 42.6 
 
Medicaid 1137 20.6 277 23.2 257 23.4 200 18.7 207 21.1 196 16.8 
Private 1442 26.1 293 24.5 235 21.4 241 22.5 326 33.2 347 29.7 
Self-pay 426 7.7 105 8.8 106 9.6 101 9.4 28 2.8 86 7.4 
No-charge 379 6.9 83 6.9 73 6.6 104 9.7 78 7.9 41 3.5 
Income by quartile <0.01 
$1-37,999 1566 28.3 296 24.6 335 30.4 322 29.9 222 22.6 391 33.5 
 
$38,000-47,999 1596 28.9 345 28.7 314 28.5 353 32.8 260 26.5 324 27.8 
$48,000-63,999 1445 26.1 286 23.8 318 28.9 263 24.4 307 31.3 271 23.2 
$64,000 or more 922 16.7 275 22.9 135 12.3 138 12.8 193 19.7 181 15.5 
Alcohol use 2186 39.5 550 45.8 483 43.8 444 41.3 291 29.6 418 35.8  
Substance abuse (non-alcohol) 348 6.3 99 8.2 77 7.0 54 5.0 44 4.5 74 6.3 <0.01 
Diabetes   1735 31.4 365 30.4 350 31.8 349 32.4 249 25.4 422 36.2 <0.01 
Hospitalization Characteristics 
Median length of stay (days) 7 (3-13) 8 (4-13) 8 (4-14) 7 (3-12) 7 (3-13) 7 (3-12) <0.01 
ICU stay 1889 34.2 406 33.8 454 41.2 379 35.2 373 38.0 277 23.7 <0.01 
Emergent admission 4128 74.7 958 79.7 904 82.0 799 74.3 683 69.6 784 67.2 <0.01 
Weekend admission 994 18.0 243 20.2 211 19.1 213 19.8 164 16.7 163 14.0 <0.01 
Complications of Cirrhosis 
Bleeding   2885 52.2 707 58.8 668 60.6 599 55.7 445 45.3 466 39.9 <0.01 
Ascites or hydrothorax  3803 68.8 778 64.7 695 63.0 727 67.6 675 68.7 928 79.5 <0.01 
SBP   228 4.1 47 3.9 45 4.1 47 4.4 54 5.5 35 3.0 0.07 
HE   1319 23.9 313 26.0 294 26.7 253 23.5 199 20.2 260 22.3 <0.01 
HRS   332 6.0 60 5.0 53 4.8 71 6.6 77 7.8 71 6.1 0.02 
HCC   167 3.0 23 1.9 22 2.0 33 3.1 45 4.6 44 3.8 <0.01 
Complications of Inpatient Hospitalizations 
Infection   1280 23.2 278 23.1 253 23.0 237 22.0 255 26.0 257 22.0 0.20 
Acute Renal Failure 1466 26.5 300 25.0 291 26.4 270 25.1 238 24.2 367 31.4 <0.01 
Electrolyte imbalance 2225 40.2 512 42.6 467 42.3 489 45.5 313 31.9 444 38.0 <0.01 
Comorbidities and Risk of Mortality 
AHRQ CM-CHF   308 5.6 73 6.1 74 6.7 60 5.6 40 4.1 61 5.2 0.10 
AHRQ CM-Coag.   2593 46.9 584 48.6 562 51.0 515 47.9 442 45.0 490 42.0 <0.01 
AHRQ CM-CRF 811 14.7 155 12.9 157 14.2 157 14.6 121 12.3 221 18.9 <0.01 
APR-DRG Risk of Mortality <0.01 
No class specified 13 0.2 0 0.0 2 0.2 0 0.0 11 1.1 0 0.0 
 
Minor likelihood of dying 200 3.6 52 4.3 40 3.6 38 3.5 21 2.1 49 4.2 
Moderate likeli ood of dying 1355 24.5 278 23.1 223 20.2 277 25.8 247 25.1 330 28.3 
Major likelihood of dying 2159 39.1 493 41.0 410 37.2 378 35.2 403 41.0 475 40.7 
Extreme likelihood of dying 1801 32.6 378 31.5 427 38.7 382 35.5 301 30.6 313 26.8 
Characteristics of Hospitals 
N of hospitals 443 278 95 39 18 13  
Hospital bed-size <0.01 
Small 32 7.2% 29 10.4% 2 2.1% 1 2.6% 0 0.0% 0 0.0% 
 
Medium 123 27.8% 97 34.9% 19 20.0% 4 10.3% 1 5.6% 2 15.4% 
Large 288 65.0% 152 54.7% 74 77.9% 34 87.2% 17 97.7% 11 84.6% 
Hospital ownership 0.03 
Government 59 13.3% 30 10.8% 15 15.8% 7 17.9% 6 33.3% 1 7.7% 
 
Private nonprofit 311 70.2% 192 69.1% 67 70.5% 29 74.4% 11 61.1% 12 92.3% 
Private proprietary 73 16.5% 56 20.1% 13 13.7% 3 7.7% 1 5.6% 0 0.0% 
Hospital teaching status <0.01 
Metropolitan non-teaching 206 46.5% 154 55.4% 43 45.3% 9 23.1% 0 0.0% 0 0.0% 
 
Metropolitan teaching 222 50.1% 110 39.6% 51 53.7% 30 76.9% 18 100.0% 13 100.0% 
Non-metropolitan 15 3.4% 14 5.0% 1 1.1% 0 0.0% 0 0.0% 0 0.0% 
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0.07 
Large metropolitan >1 million residents 263 59.4% 163 58.6% 59 62.1% 20 51.3% 9 50.0% 12 92.3% 
 
Small metropolitan <1 million residents 165 37.2% 101 36.3% 35 36.8% 19 48.7% 9 50.0% 1 7.7% 
Micropolitan 15 3.4% 14 5.0% 1 1.1% 0 0.0% 0 0.0% 0 0.0% 
Liver transplant hospital 49 11.1% 1 0.4% 5 5.3% 15 38.5% 15 83.3% 13 100.0% <0.01 
Table 1: Inpatient mortality, characteristics of patients, hospitalizations and hospitals for each quintile of annual 
procedure volume. NAFLD: Non-alcoholic fatty liver disease, ICU: Intensive care unit, SBP: Spontaneous 
bacterial peritonitis, HE: hepatic encephalopathy, HRS: hepatorenal syndrome, HCC: hepatocellular 
carcinoma, AHRQ CM: Agency for Healthcare Research and Quality Co-morbidity Measures, APR-DRG: All 
Patient Refined Diagnosis Related Groups. 
 
 
 
All Patients aOR 95% CI p value c-statistic 
Annual procedure volume 
0.776 
1-4 TIPS/year 1.9 1.21-3.01 0.01 
5-9 TIPS/year 2.0 1.25-3.17 <0.01 
10-19 TIPS/year 1.9 1.17-3.00 0.01 
20-29 TIPS/year 1.4 0.84-2.34 0.19 
≥30 TIPS/year Reference 
AHRQ comorbidity measures 
Congestive heart failure 1.4 0.85-2.31 0.18 
Coagulopathy 2.0 1.46-2.62 <0.01 
Renal failure 1.5 1.06-2.21 0.03 
Income quartile for patient zip code  
$1-37,999 0.9 0.60-1.29 0.51 
$38,000-47,999 0.5 0.36-0.82 <0.01 
$48,000-63,999 0.6 0.38-0.90 0.01 
$64,000 or more Reference 
Other risk factors    
Age (per 1 year increase) 1.0 1.01-1.04 <0.01 
Alcoholic liver disease 1.0 0.78-1.40 0.76 
Emergent admission 1.4 0.88-1.04 0.16 
Variceal Bleeding 2.3 1.65-3.21 <0.01 
Infection 3.9 3.00-5.18 <0.01 
Diabetes 0.8 0.55-1.04 0.08 
 
Table 2: Multivariate model for inpatient mortality after TIPS hospitalization. 
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tAPPENDIX TABLES  
Code Description 
Liver Transplant 
Procedure  
50.51 AUXILIARY LIVER TRANSPLANT 
50.59 OTHER TRANSPLANT OF LIVER 
Diagnosis  
996.82 COMPLICATIONS OF TRANSPLANTED LIVER 
Etiology of Liver Disease 
Alcoholic Liver Disease 
571.0 ALCOHOLIC FATTY LIVER  
571.1 ACUTE ALCOHOLIC HEPATITIS 
571.2 ALCOHOLIC CIRRHOSIS OF LIVER 
571.3 UNSPECIFIED ALCOHOLIC LIVER DAMAGE 
Non-Alcoholic Fatty Liver Disease 
571.5 CIRRHOSIS OF LIVER WITHOUT MENTION OF ALCOHOL 
571.8 OTHER CHRONIC NON-ALCOHOLIC LIVER DISEASE 
Viral Disease 
Hepatitis B 
070.20 VIRAL HEP B W/HEP COMA ACUTE/UNSPECIFIED W/O HEP DELTA 
070.22 VIRAL HEP B W/HEP COMA CHRN W/O MENTION HEP DELTA 
070.23 HEPATITIS B, CHRONIC, W HEPATIC COMA, W HEPATITIS DELTA 
070.30 VIRAL HEP B W/O HEP COMA ACUT/UNS W/O HEP DELTA 
070.32 VIRAL HEP B W/O HEP COMA CHRN W/O HEP DELTA 
070.33 VIRAL HEP B W/O MENTION HEP COMA CHRN W/HEP DELTA 
Hepatitis C 
070.41  ACUTE HEPATITIS C WITH HEPATIC COMA 
070.44 CHRONIC HEPATITIS C WITH HEPATIC COMA 
070.51 ACUTE HEPATITIS C WITHOUT MENTION HEPATIC COMA 
070.54 CHRONIC HEPATITIS C WITHOUT MENTION HEPATIC COMA 
070.70 UNSPECIFIED VIRAL HEPATITIS C W/O HEPATIC COMA 
070.71 UNSPECIFIED VIRAL HEPATITIS C WITH HEPATIC COMA 
070.59 OTHER SPECIFIED VIRAL HEPATITIS WITHOUT MENTION HEP COMA 
Other Liver Diseases 
Non-Specific or Other Specified Hepatitis 
571.40 UNSPECIFIED CHRONIC HEPATITIS 
571.49 OTHER CHRONIC HEPATITIS 
571.9 UNSPEC CHRONIC LIVER DISEASE W/O MENTION OF ALCOHOL 
078.5 CYTOMEGALIC INCLUSION VIRUS HEPATITIS 
Autoimmune Hepatitis 
571.42 AUTOIMMUNE HEPATITIS 
Wilson's Disease 
275.1 DISORDERS OF COPPER METABOLISM 
Alpha-1-Antitrypsin Deficiency 
273.4 ALPHA 1 ANTITRYPSIN DEFICIENCY 
Non-Specific Cirrhosis 
571.6 PRIMARY BILIARY CIRRHOSIS 
Other Chronic Liver Disease 
573.0 CHRONIC PASSIVE CONGESTION OF LIVER 
573.4 HEPATIC INFARCTION 
573.9 UNSPECIFIED DISORDER OF LIVER 
Alcohol use 
291.0 ALCOHOL WITHDRAWAL DELIRIUM 
291.1 ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER 
291.2 ALCOHOL-INDUCED PERSISTING DEMENTIA 
291.3 ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS 
291.4 IDIOSYNCRATIC ALCOHOL INTOXICATION 
291.5 ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS 
291.8 OTHER SPECIFIED ALCOHOL-INDUCED MENTAL DISORDERS 
291.81 ALCOHOL WITHDRAWAL 
291.82 ALCOHOL-INDUCED SLEEP DISORDERS 
291.89 OTHER ALCOHOL-INDUCED DISORDERS 
291.9 UNSPECIFIED ALCOHOL-INDUCED MENTAL DISORDERS 
303.00-03 ACUTE ALCOHOL INTOXICATION 
303.90-93 OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE 
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t305.00-03 ALCOHOL ABUSE 357.5 ALCOHOLIC POLYNEUROPATHY 425.5 ALCOHOLIC CARDIOMYOPATHY 
535.30-31 ALCOHOLIC GASTRITIS 
Substance use (other than alcohol) 
292.0 DRUG WITHDRAWAL 
292.11 DRUG-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS 
292.12 DRUG-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS 
292.2 PATHOLOGICAL DRUG INTOXICATION 
292.81 DRUG-INDUCED DELIRIUM 
292.82 DRUG-INDUCED PERSISTING DEMENTIA 
292.83 DRUG-INDUCED PERSISTING AMNESTIC DISORDER 
292.84 DRUG-INDUCED MOOD DISORDER 
292.85 DRUG INDUCED SLEEP DISORDERS 
292.89 OTHER SPECIFIED DRUG-INDUCED MENTAL DISORDERS 
292.9 UNSPECIFIED DRUG-INDUCED MENTAL DISORDER 
304.00-03 OPIOID TYPE DEPENDENCE 
304.10-13 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE 
304.20-23 COCAINE DEPENDENCE 
304.30-33 CANNABIS DEPENDENCE 
304.40-43 AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE 
304.50-53 HALLUCINOGEN DEPENDENCE 
304.60-63 OTHER SPECIFIED DRUG DEPENDENCE 
304.70-73 COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE 
304.80-83 COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG 
304.90-93 UNSPECIFIED DRUG DEPENDENCE 
305.20-23 CANNABIS ABUSE 
305.30-33 HALLUCINOGEN ABUSE 
305.40-43 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE 
305.50-53 OPIOID ABUSE 
305.60-63 COCAINE ABUSE 
305.70-73 AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE 
305.90-93 OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE 
648.30-34 DRUG DEPENDENCE COMPLICATING PREGNANCY, CHILDBIRTH, OR THE PUERPERIUM 
965.00 POISONING BY OPIUM (ALKALOIDS), UNSPECIFIED 
965.01 POISONING BY HEROIN 
965.02 POISONING BY METHADONE 
965.09 POISONING BY OTHER OPIATES AND RELATED NARCOTICS 
969.6 POISONING BY PSYCHODYSLEPTICS (HALLUCINOGENS) 
970.81 POISONING BY COCAINE 
V654.2 COUNSELING, SUBSTANCE USE 
Diabetes 
250.00-03 DIABETES MELLITUS WITHOUT MENTION OF COMPLICATION 
250.10-13 DIABETES WITH KETOACIDOSIS 
250.20-23 DIABETES WITH HYPEROSMOLARITY 
250.40-43 DIABETES WITH RENAL MANIFESTATIONS 
250.50-53 DIABETES WITH OPHTHALMIC MANIFESTATIONS 
250.60-63 DIABETES WITH NEUROLOGICAL MANIFESTATIONS 
250.70-73 DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS 
250.80-83 DIABETES WITH OTHER SPECIFIED MANIFESTATIONS 
250.90-93 DIABETES WITH UNSPECIFIED COMPLICATION 
Variceal Bleeding 
Diagnosis 
456.0 ESOPHAGEAL VARICES WITH BLEEDING 
456.20 ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE, WITH BLEEDING 
530.82 ESOPHAGEAL HEMORRHAGE 
569.3 HEMORRHAGE OF RECTUM AND ANUS 
578.0 HEMATEMESIS 
578.1 BLOOD IN STOOL 
578.9 HEMORRHAGE OF GASTROINTESTINAL TRACT, UNSPECIFIED 
Procedure (endoscopy) 
42.33 ENDOSCOPIC EXCISION OR DESTRUCTION OF LESION OR TISSUE OF ESOPHAGUS 
43.41 ENDOSCOPIC EXCISION OR DESTRUCTION OF LESION OR TISSUE OF STOMACH 
44.43 ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING 
45.13 OTHER ENDOSCOPY OF SMALL INTESTINE 
45.16 ESOPHAGOGASTRODUODENOSCOPY [EGD] WITH CLOSED BIOPSY 
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t45.23 COLONOSCOPY Ascites and hydrothorax Diagnosis 
511.89 OTHER SPECIFIED FORMS OF EFFUSION, EXCEPT TUBERCULOUS 
789.59 OTHER ASCITES 
276.69 OTHER FLUID OVERLOAD 
511.9 UNSPECIFIED PLEURAL EFFUSION 
Procedure (percutaneous drainage) 
54.91 PERCUTANEOUS ABDOMINAL DRAINAGE 
34.91 THORACENTESIS 
Hepatic encephalopathy 
572.2 HEPATIC ENCEPHALOPATHY 
348.39 OTHER ENCEPHALOPATHY 
Other complications 
567.23 SPONTANEOUS BACTERIAL PERITONITIS 
572.4 HEPATORENAL SYNDROME 
155.0 MALIGNANT NEOPLASM OF LIVER, PRIMARY 
584.5-9 ACUTE RENAL FAILURE 
Electrolyte imbalance 
276.1 HYPOSMOLALITY AND/OR HYPONATREMIA 
276.2 ACIDOSIS 
276.8 HYPOPOTASSEMIA 
Infection   
481-486 PNEUMONIA 
682.2-9 CELLULITIS 
790.7 BACTEREMIA 
576.1 CHOLANGITIS 
008.45 INTESTINAL INFECTION DUE TO CLOSTRIDIUM DIFFICILE 
Sepsis 
995.91-92 SEPSIS 
785.52 SEPTIC SHOCK 
038.0-9 SEPTICEMIA 
Urinary tract infection 
599.0 URINARY TRACT INFECTION, SITE NOT SPECIFIED 
590.80 PYELONEPHRITIS, UNSPECIFIED 
ICU stay 
785.50,51,59 SHOCK (Diagnosis) 
Procedure 
00.17 INFUSION OF VASOPRESSOR AGENT 
31.1 TEMPORARY TRACHEOSTOMY 
37.61,62,68 IMPLANT OF HEART & CIRCULATORY ASSIST SYSTEM 
37.78 INSERTION OF TEMPORARY TRANSVENOUS PACEMAKER SYSTEM 
38.91 ARTERIAL CATHETERIZATION 
39.65 EXTRACORPOREAL MEMBRANE OXYGENATION [ECMO] 
39.95 HEMODIALYSIS 
54.98 PERITONEAL DIALYSIS 
89.60 CONTINUOUS INTRA-ARTERIAL BLOOD GAS MONITORING 
89.62 CENTRAL VENOUS PRESSURE MONITORING 
89.64 PULMONARY ARTERY WEDGE MONITORING 
89.67 MONITORING OF CARDIAC OUTPUT BY OXYGEN CONSUMPTION TECHNIQUE 
89.68 MONITORING OF CARDIAC OUTPUT BY OTHER TECHNIQUE 
93.90,91,99 RESPIRATORY THERAPY 
96.6 ENTERAL INFUSION OF CONCENTRATED NUTRITIONAL SUBSTANCES 
99.15 PARENTERAL INFUSION OF CONCENTRATED NUTRITIONAL SUBSTANCES 
96.70-72 OTHER INVASIVE MECHANICAL VENTILATION 
97.23 REPLACEMENT OF TRACHEOSTOMY TUBE 
97.37 REMOVAL OF TRACHEOSTOMY TUBE 
99.60-63 CARDIOPULMONARY RESUSCITATION 
99.78 AQUAPHERESIS 
99.81 HYPOTHERMIA (CENTRAL) (LOCAL) 
 
Appendix Table 1 List of International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes 
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t Univariate analysis Patient  OR 95% CI p Age 1 year increase 1.0 1.00-1.02 <0.01 
Gender Female vs male 0.8 0.63-0.91 <0.01 
Primary insurance payer    <0.01 
 Medicaid vs Medicare 1.1 0.88-1.38  
 Private vs Medicare 0.8 0.64-1.01  
 Self-pay vs Medicare 1.5 1.12-2.03  
 No-charge vs Medicare 0.9 0.63-1.31  
Etiology of liver disease    <0.01 
 NAFLD vs alcoholic  0.6 0.48-0.76  
 Viral vs alcoholic 0.7 0.55-0.89  
 Other vs alcoholic 1.1 0.81-1.37  
Income range for the zip 
code  
   <0.01 
 $1-37,999 vs $64,000 or more 1.1 0.84-1.36  
 $38,000-47,999 vs $64,000 or more 0.6 0.49-0.83  
 $48,000-63,999 vs $64,000 or more 0.6 0.47-0.81  
Substance abuse (non-
alcohol) 
Yes vs no 0.8 0.55-1.17 0.25 
Diabetes   Yes vs no 0.7 0.59-0.88 <0.01 
Hospitalization 
Characteristics     
Length of stay 1 day increase 1.0 1.01-1.03 <0.01 
Elective admission Emergent vs elective 3.1 2.34-4.00 <0.01 
Admission day Weekend vs weekday 1.8 1.45-2.15 <0.01 
ICU stay Yes vs no 16.0 12.57-20.45 <0.01 
Hospital     
Annual procedure volume    <0.01 
 1-4 TIPS/year vs ≥30 TIPS/year 2.3 1.72-3.11  
 5-9 TIPS/year vs ≥30 TIPS/year 2.4 1.77-3.20  
 10-19 TIPS/year vs ≥30 TIPS/year 2.1 1.51-2.78  
 20-29 TIPS/year vs ≥30 TIPS/year 1.5 1.11-2.12  
Hospital bed-size    0.63 
 Small vs large 1.1 0.67-1.88  
 Medium vs large 1.1 0.89-1.39  
Hospital ownership    0.50 
 Government vs private proprietary 1.2 0.86-1.78  
 Private nonprofit vs private proprietary 1.1 0.81-1.47  
Hospital teaching status    0.19 
 Metropolitan non-teaching vs non-metropolitan 2.2 0.81-5.78  
 Metropolitan teaching vs non-metropolitan 2.0 0.74-5.20  
Hospital urban-rural location    0.28 
 large metropolitan >1 million residents vs micropolitan 2.0 0.75-5.27  
 small metropolitan <1 million residents vs micropolitan 2.0 0.77-5.42  
Liver transplant status Transplant hospital vs non-transplant hospital 0.7 0.55-0.79 <0.01 
Complication of cirrhosis     
Variceal bleeding Yes vs no 3.0 2.47-3.65 <0.01 
SBP Yes vs no 1.4 0.97-2.08 0.07 
HE Yes vs no 2.3 1.90-2.71 <0.01 
HRS Yes vs no 5.4 4.24-6.91 <0.01 
Ascites or hydrothorax Yes vs no 1.1 0.95-1.39 0.15 
Complications of Inpatient 
Hospitalizations     
Infection   Yes vs no 4.4 3.73-5.31 <0.01 
Acute Renal Failure Yes vs no 7.8 6.46-9.38 <0.01 
Electrolyte imbalance Yes vs no 3.9 3.20-4.64 <0.01 
 
Appendix Table 2 Crude Odds Ratios for Inpatient Mortality 
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A
ut
ho
r M
an
us
cr
ip
t Elective admissions only OR 95% CI p value c-statistics 
Annual Procedure volume 
0.895 
1-19 vs. ≥20 TIPS/year 2.7 1.10-6.41 0.03
AHRQ Comorbidity measures 
Congestive heart failure 0.9 0.15-5.26 0.91
Coagulopathy 4.2 1.89-9.52 <0.01
Renal failure 0.4 0.10-1.35 0.13
Income quartile for patient zip code  
$1-37,999 0.7 0.23-2.07 0.50
$38,000-47,999 0.6 0.21-1.95 0.43
$48,000-63,999 1.1 0.35-3.13 0.93
$64,000 or more Reference   
Other Risk Fa tors 
Age (per 1 year increase) 1.0 0.94-1.01 0.13
Alcoholic liver disease 0.7 0.30-1.78 0.50
Variceal Bleeding 4.5 2.00-10.10 <0.01
Infection 7.8 3.50-17.54 <0.01
Diabetes 0.6 0.23-1.41 0.22
Appendix Table 3: Multivariate model for inpatient mortality after elective admissions for TIPS. 
 
Emergent admissions only OR 95% CI p value c-statistics 
Annual Procedure Volume 
0.738 
1-19 vs. ≥20 TIPS/year 1.5 1.11-2.15 0.01
Comorbidity measures 
Congestive heart failure 1.5 0.89-2.59 0.13
Coagulopathy 1.8 1.29-2.45 <0.01
Renal failure 1.8 1.19-2.64 0.01
Income quartile for patient zip code    
$1-37,999 0.9 0.59-1.35 0.60
$38,000-47,999 0.5 0.33-0.80 <0.01
$48,000-63,999 0.6 0.35-0.88 0.01
$64,000 or more Reference  
Other Risk Factors   
Age (per 1 year increase) 1.0 1.00-1.03 0.02
Alcoholic liver disease 1.1 0.80-1.51 0.55
Variceal Bleeding 2.1 1.44-2.97 <0.01
Infection 3.5 2.63-4.77 <0.01
Diabetes 0.8 0.54-1.08 0.13
Appendix Table 4: Multivariate model for inpatient mortality after emergent admissions for TIPS. 
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